| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447308 | European Journal of Cancer | 2011 | 10 Pages |
Abstract
Even after accounting for prognostic profile, patients still benefit from a nephrectomy; an approximately 50% reduction in mortality was observed. It is, therefore, recommended that patients with metastasised disease receive cytoreductive surgery when there is no contraindication. Trial results on cytoreductive surgery combined with targeted molecular therapeutics are awaited for.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
K.K.H. Aben, S. Heskamp, M.L. Janssen-Heijnen, E.L. Koldewijn, C.M. van Herpen, L.A. Kiemeney, E. Oosterwijk, D.J. van Spronsen,